For decades, general health and science information has served as the foundation for public understanding of medical conditions and treatment options. This legacy context has enabled individuals to recognize when their personal health history may intersect with specific pharmaceutical interventions. Within this framework, patients have learned to monitor their own wellness trajectories and identify potential concerns that warrant further investigation. The transition from broad health awareness to a more focused occupational exposure concern begins with recognizing that certain therapeutic contexts carry distinct risk profiles. When a patient has been prescribed a medication such as Tysabri, the general health literacy acquired through mainstream information channels becomes directly applicable to assessing personal exposure history. This is particularly relevant for individuals who may have experienced symptoms consistent with Progressive Multifocal Leukoencephalopathy following treatment.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri specifically due to this risk, noting that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and postmarketing surveillance. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals. In Tysabri-treated patients, the infection arises from reactivation of the JC virus, which is normally kept in check by the immune system. Tysabri works by blocking the alpha-4 integrin receptor on immune cells, preventing them from crossing the blood-brain barrier. While this reduces inflammatory activity in multiple sclerosis, it also impairs immune surveillance in the central nervous system, allowing JC virus to replicate unchecked and infect oligodendrocytes, the cells that produce myelin. This mechanistic pathway is central to understanding why Tysabri increases PML risk.
Clinical trial data show that PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 multiple sclerosis patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These numbers underscore that PML is a rare but serious adverse effect. Three risk factors for developing PML on Tysabri have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk. The duration of therapy is a critical factor; risk increases with continued exposure, particularly after 24 months. Prior immunosuppressant use, such as with other disease-modifying therapies for multiple sclerosis or Crohn's disease, further elevates risk. These factors should be considered when initiating and continuing treatment, weighing expected benefit against PML risk.
The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The FDA boxed warning clearly states that Tysabri increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also mandates monitoring and immediate withholding of Tysabri at the first sign or symptom suggestive of PML. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients and healthcare providers are aware of the risks and that appropriate monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients and their families have alleged that the warnings were insufficient or that the risks were not adequately communicated, leading to lawsuits. For patients who have developed PML after Tysabri treatment, legal considerations may include whether the prescribing physician adequately discussed the risks, whether the patient's risk factors (such as anti-JCV antibody status or prior immunosuppressant use) were properly assessed, and whether the timing of diagnosis and treatment withdrawal was appropriate. The timeline between exposure and documented harm is important: PML typically occurs after prolonged Tysabri use, often beyond two years, but cases have been reported after shorter durations. In clinical trials, one Crohn's disease patient developed PML after only eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability complicates legal claims, as the latency period can be months to years. Attorney-related considerations for affected patients include the need to establish that the harm was caused by Tysabri and that the manufacturer or healthcare provider failed to meet the standard of care. Evidence of inadequate risk communication, failure to monitor for PML symptoms, or delay in diagnosis may support a claim. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances, including medical records, treatment history, and the timing of PML diagnosis relative to Tysabri exposure.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of blocking immune cell entry into the brain. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three main risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
You may have legal recourse if you believe the risks were not adequately communicated or managed. Consult an attorney experienced in pharmaceutical litigation to evaluate your case, considering factors such as adequacy of warnings, monitoring, and timing of diagnosis.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.